|
시장보고서
상품코드
1807720
세계의 피하 면역글로불린 시장 규모, 점유율, 동향, 업계 분석 : 제품별, 용도별, 최종 용도별, 지역별 - 시장 예측(2025-2034년)Subcutaneous Immunoglobulin Market Size, Share, Trends, & Industry Analysis Report By Product (IgG, IgA, and IgM), By Application, By End Use, and By Region - Market Forecast, 2025-2034 |
||||||
Polaris Market Research의 최신 조사에 따르면 피하 면역글로불린 시장 규모는 2034년까지 267억 8,000만 달러에 달할 전망입니다. 이 리포트에서는 현재 시장 역학의 상세 인사이트와 향후 시장 성장에 관한 분석을 제공하고 있습니다.
피하면역글로불린(SCIg)은 면역결핍증 환자의 면역체계를 안정적으로 유지하는 데 도움이 되는 항체를 피하로 투여하는 치료법입니다. 이 시장은 SCIg가 환자에게 제공하는 편의성과 자율성에 힘입어 재택 치료로의 전환이 진행됨에 따라 확대되고 있습니다. 병원에 의존하는 수액과 달리 SCIg는 익숙한 환경에서 치료를 관리할 수 있으며, 잦은 병원 방문에 대한 부담을 줄일 수 있습니다. 이러한 유연성은 치료 순응도를 높이고 환자의 전반적인 만족도와 삶의 질을 향상시켜 SCIg가 바람직한 형태의 면역글로불린 치료제로서의 역할을 강화합니다.
피하 면역글로불린 시장은 전달 장치 및 주입 기술의 지속적인 혁신으로 인해 더욱 견인되고 있습니다. 휴대용 펌프, 프리필드 시린지 등 사용하기 쉬운 시스템의 개발로 투약 과정이 간소화되어 더 많은 환자층이 쉽게 치료를 받을 수 있게 되었습니다. 이러한 발전은 치료의 복잡성과 시간을 줄이고, 도입 장벽을 최소화하는 데 기여하고 있습니다. 기술의 발전은 특히 SCIg의 치료 범위를 확장하고 편의성과 효율성에 대한 수요 증가와 맞물려 장기적인 면역요법 관리에서 SCIg의 존재감을 강화하고 있습니다.
피하 면역글로불린 시장 : 분석 개요
제품별로는 IgG가 2024년 매출 점유율을 독점하고 있습니다. IgG는 광범위한 원발성 및 이차성 면역결핍증 치료에 효과적으로 사용되는 주요 면역글로불린의 아이소유형이기 때문입니다.
용도별로는 후천성 면역 결핍을 유발할 수 있는 암, 자가면역질환 등의 질환이 전 세계에서 증가하고 있는 것이 이차성 면역 결핍 분야의 성장을 촉진하고 있습니다.
북미는 정교한 의료 시스템과 첨단 치료 솔루션의 빠른 통합으로 2024년 SCIG 세계 시장을 주도했습니다.
아시아태평양은 대규모 의료 투자, 질병에 대한 인식 개선, 최신 치료법에 대한 접근성 향상으로 인해 가장 높은 성장률을 나타낼 것으로 예측됩니다.
세계의 주요 기업에는 Baxter, Biotest, CSL Behring, GC Biopharma USA, Inc., Grifols, Kamada Ltd., LFB, Nufactor, Octapharma, Takeda 등이 있습니다.
목차
제1장 서론
제2장 개요
제3장 분석 방법
제4장 세계의 피하 면역글로불린 시장 인사이트
- 시장 스냅숏
- 피하 면역글로불린 시장 역학
- 촉진요인과 기회
- 면역 부전 질환의 유병률 증가
- 제제 기술의 진보
- 억제요인과 과제
- 고액의 치료비
- 촉진요인과 기회
- PESTLE 분석
- 피하 면역글로불린 시장의 동향
- 밸류체인 분석
제5장 피하 면역글로불린 시장 : 제품 유형별
- 주요 조사 결과
- 서론
- IgG
- IgA
- IgM
제6장 피하 면역글로불린 시장 : 용도별
- 주요 조사 결과
- 서론
- 원발성 면역 부전증
- 2차성 면역 부전증
제7장 피하 면역글로불린 시장 : 최종 용도별
- 주요 조사 결과
- 서론
- 병원
- 재택 의료
- 진료소
- 기타
제8장 피하 면역글로불린 시장 : 지역별
- 주요 분석 결과
- 서론
- 피하 면역글로불린 시장 분석 : 지역별(2020-2034년)
- 북미
- 북미 : 제품 유형별, 지역별(2020-2034년)
- 북미 : 용도별, 지역별(2020-2034년)
- 북미 : 최종 용도별, 지역별(2020-2034년)
- 미국
- 캐나다
- 유럽
- 유럽 : 제품 유형별, 지역별(2020-2034년)
- 유럽 : 용도별, 지역별(2020-2034년)
- 유럽 : 최종 용도별, 지역별(2020-2034년)
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 제품 유형별, 지역별(2020-2034년)
- 아시아태평양 : 용도별, 지역별(2020-2034년)
- 아시아태평양 : 최종 용도별, 지역별(2020-2034년)
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 제품 유형별, 지역별(2020-2034년)
- 중동 및 아프리카 : 용도별, 지역별(2020-2034년)
- 중동 및 아프리카 : 최종 용도별, 지역별(2020-2034년)
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 제품 유형별, 지역별(2020-2034년)
- 라틴아메리카 : 용도별, 지역별(2020-2034년)
- 라틴아메리카 : 최종 용도별, 지역별(2020-2034년)
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제9장 경쟁 구도
- 확대와 인수 분석
- 확대
- 인수
- 제휴/협업/합의/공개
제10장 기업 개요
- Baxter
- Biotest
- CSL Behring
- GC Biopharma USA, Inc.
- Grifols
- Kamada Ltd.
- LFB
- Nufactor
- Octapharma
- Takeda
The subcutaneous immunoglobulin market size is expected to reach USD 26.78 billion by 2034, according to a new study by Polaris Market Research. The report "Subcutaneous Immunoglobulin Market Share, Size, Trends, Industry Analysis Report: By Product (IgG, IgA, and IgM), By Application, By End Use, and By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Subcutaneous immunoglobulin (SCIg) is a therapy administered under the skin to deliver antibodies that help maintain immune system stability in patients with immunodeficiency disorders. This market is witnessing expansion due to the growing shift toward home-based treatments, driven by the convenience and autonomy that SCIg offers patients. Unlike hospital-dependent infusions, SCIg enables individuals to manage their therapy in familiar settings, reducing the burden of frequent clinical visits. This flexibility improves treatment adherence and also enhances overall patient satisfaction and quality of life, reinforcing SCIg's role as a preferred mode of immunoglobulin therapy.
The subcutaneous immunoglobulin market is further driven by the continuous innovation in delivery devices and infusion technologies. The development of user-friendly systems, such as portable pumps and pre-filled syringes, is simplifying the administration process and making therapy more accessible to a wider patient base. These advancements reduce the complexity and time associated with treatment, minimizing barriers to adoption. Technological progress is especially expanding the therapeutic reach of SCIg and strengthening its presence in long-term immunotherapy management by aligning with the growing demand for convenience and efficiency.
Subcutaneous Immunoglobulin Market Report Highlights
In terms of product, the IgG dominated the revenue share in 2024, as it is the primary immunoglobulin isotype used to effectively treat a wide range of primary and secondary immunodeficiency disorders.
Based on application, the secondary immunodeficiency segment growth is driven by the increasing global incidence of conditions like cancer and autoimmune diseases, which can cause acquired immune deficiencies.
North America led the global SCIG market in 2024, fueled by its refined healthcare systems and rapid integration of advanced therapeutic solutions.
Asia Pacific region is anticipated to register the highest growth rate, propelled by major healthcare investments, greater disease awareness, and improved access to modern treatments.
A few global key market players include Baxter; Biotest; CSL Behring; GC Biopharma USA, Inc.; Grifols; Kamada Ltd.; LFB; Nufactor; Octapharma; and Takeda.
Polaris Market Research has segmented the market report on the basis product type, application, end use, and region:
By Product Type Outlook (Revenue, USD Billion, 2020-2034)
IgG
IgA
IgM
By Application Outlook (Revenue, USD Billion, 2020-2034)
Primary Immunodeficiency Disease
Secondary Immunodeficiency Disease
By End Use (Revenue, USD Billion, 2020-2034)
Hospitals
Homecare
Clinics
Others
By Regional Outlook (Revenue, USD Billion, 2020-2034)
North America
US
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Vietnam
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Subcutaneous Immunoglobulin Market Insights
- 4.1. Subcutaneous Immunoglobulin Market - Market Snapshot
- 4.2. Subcutaneous Immunoglobulin Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Growth in Prevalence of Immunodeficiency Diseases
- 4.2.1.2. Rising Advancement in Formulation Technology
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High Treatment Cost
- 4.2.3. Public opinion and privacy legal precedents
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Subcutaneous Immunoglobulin Market Trends
- 4.6. Value Chain Analysis
5. Subcutaneous Immunoglobulin Market, By Product Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Subcutaneous Immunoglobulin Market, By Product Type, by Region, 2020-2034 (USD Billion)
- 5.3. IgG
- 5.3.1. Subcutaneous Immunoglobulin Market, by IgG, by Region, 2020-2034 (USD Billion)
- 5.4. IgA
- 5.4.1. Subcutaneous Immunoglobulin Market, by IgA, by Region, 2020-2034 (USD Billion)
- 5.5. IgM
- 5.5.1. Subcutaneous Immunoglobulin Market, by IgM, by Region, 2020-2034 (USD Billion)
6. Subcutaneous Immunoglobulin Market, By Application
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Subcutaneous Immunoglobulin Market, By Application, by Region, 2020-2034 (USD Billion)
- 6.3. Primary Immunodeficiency Disease
- 6.3.1. Subcutaneous Immunoglobulin Market, by Primary Immunodeficiency Disease, by Region, 2020-2034 (USD Billion)
- 6.4. Secondary Immunodeficiency Disease
- 6.4.1. Subcutaneous Immunoglobulin Market, by Secondary Immunodeficiency Disease, by Region, 2020-2034 (USD Billion)
7. Subcutaneous Immunoglobulin Market, By End Use
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Subcutaneous Immunoglobulin Market, By End Use, by Region, 2020-2034 (USD Billion)
- 7.3. Hospitals
- 7.3.1. Subcutaneous Immunoglobulin Market, by Hospitals, by Region, 2020-2034 (USD Billion)
- 7.4. Homecare
- 7.4.1. Subcutaneous Immunoglobulin Market, by Homecare, by Region, 2020-2034 (USD Billion)
- 7.5. Clinics
- 7.5.1. Subcutaneous Immunoglobulin Market, by Clinics, by Region, 2020-2034 (USD Billion)
- 7.6. Others
- 7.6.1. Subcutaneous Immunoglobulin Market, by Others, by Region, 2020-2034 (USD Billion)
8. Subcutaneous Immunoglobulin Market, by Geography
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Subcutaneous Immunoglobulin Market Assessment, By Geography, by Region, 2020-2034 (USD Billion)
- 8.3. Subcutaneous Immunoglobulin Market - North America
- 8.3.1. North America: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.3.2. North America: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.3.3. North America: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.3.4. Subcutaneous Immunoglobulin Market - US
- 8.3.4.1. US: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.3.4.2. US: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.3.4.3. US: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.3.5. Subcutaneous Immunoglobulin Market - Canada
- 8.3.5.1. Canada: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.3.5.2. Canada: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.3.5.3. Canada: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.4. Subcutaneous Immunoglobulin Market - Europe
- 8.4.1. Europe: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.4.2. Europe: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.4.3. Europe: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.4.4. Subcutaneous Immunoglobulin Market - UK
- 8.4.4.1. UK: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.4.4.2. UK: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.4.4.3. UK: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.4.5. Subcutaneous Immunoglobulin Market - France
- 8.4.5.1. France: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.4.5.2. France: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.4.5.3. France: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.4.6. Subcutaneous Immunoglobulin Market - Germany
- 8.4.6.1. Germany: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.4.6.2. Germany: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.4.6.3. Germany: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.4.7. Subcutaneous Immunoglobulin Market - Italy
- 8.4.7.1. Italy: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.4.7.2. Italy: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.4.7.3. Italy: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.4.8. Subcutaneous Immunoglobulin Market - Spain
- 8.4.8.1. Spain: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.4.8.2. Spain: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.4.8.3. Spain: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.4.9. Subcutaneous Immunoglobulin Market - Netherlands
- 8.4.9.1. Netherlands: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.4.9.2. Netherlands: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.4.9.3. Netherlands: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.4.10. Subcutaneous Immunoglobulin Market - Russia
- 8.4.10.1. Russia: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.4.10.2. Russia: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.4.10.3. Russia: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.4.11. Subcutaneous Immunoglobulin Market - Rest of Europe
- 8.4.11.1. Rest of Europe: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.4.11.2. Rest of Europe: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.4.11.3. Rest of Europe: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.5. Subcutaneous Immunoglobulin Market - Asia Pacific
- 8.5.1. Asia Pacific: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.5.2. Asia Pacific: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.5.3. Asia Pacific: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.5.4. Subcutaneous Immunoglobulin Market - China
- 8.5.4.1. China: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.5.4.2. China: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.5.4.3. China: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.5.5. Subcutaneous Immunoglobulin Market - India
- 8.5.5.1. India: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.5.5.2. India: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.5.5.3. India: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.5.6. Subcutaneous Immunoglobulin Market - Malaysia
- 8.5.6.1. Malaysia: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.5.6.2. Malaysia: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.5.6.3. Malaysia: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.5.7. Subcutaneous Immunoglobulin Market - Japan
- 8.5.7.1. Japan: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.5.7.2. Japan: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.5.7.3. Japan: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.5.8. Subcutaneous Immunoglobulin Market - Indonesia
- 8.5.8.1. Indonesia: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.5.8.2. Indonesia: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.5.8.3. Indonesia: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.5.9. Subcutaneous Immunoglobulin Market - South Korea
- 8.5.9.1. South Korea: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.5.9.2. South Korea: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.5.9.3. South Korea: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.5.10. Subcutaneous Immunoglobulin Market - Australia
- 8.5.10.1. Australia: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.5.10.2. Australia: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.5.10.3. Australia: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.5.11. Subcutaneous Immunoglobulin Market - Rest of Asia Pacific
- 8.5.11.1. Rest of Asia Pacific: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.5.11.2. Rest of Asia Pacific: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.5.11.3. Rest of Asia Pacific: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.6. Subcutaneous Immunoglobulin Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.6.2. Middle East & Africa: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.6.3. Middle East & Africa: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.6.4. Subcutaneous Immunoglobulin Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.6.4.2. Saudi Arabia: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.6.4.3. Saudi Arabia: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.6.5. Subcutaneous Immunoglobulin Market - UAE
- 8.6.5.1. UAE: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.6.5.2. UAE: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.6.5.3. UAE: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.6.6. Subcutaneous Immunoglobulin Market - Israel
- 8.6.6.1. Israel: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.6.6.2. Israel: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.6.6.3. Israel: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.6.7. Subcutaneous Immunoglobulin Market - South Africa
- 8.6.7.1. South Africa: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.6.7.2. South Africa: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.6.7.3. South Africa: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.6.8. Subcutaneous Immunoglobulin Market - Rest of Middle East & Africa
- 8.6.8.1. Rest of Middle East & Africa: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.6.8.2. Rest of Middle East & Africa: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.6.8.3. Rest of Middle East & Africa: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.7. Subcutaneous Immunoglobulin Market - Latin America
- 8.7.1. Latin America: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.7.2. Latin America: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.7.3. Latin America: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.7.4. Subcutaneous Immunoglobulin Market - Mexico
- 8.7.4.1. Mexico: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.7.4.2. Mexico: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.7.4.3. Mexico: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.7.5. Subcutaneous Immunoglobulin Market - Brazil
- 8.7.5.1. Brazil: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.7.5.2. Brazil: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.7.5.3. Brazil: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.7.6. Subcutaneous Immunoglobulin Market - Argentina
- 8.7.6.1. Argentina: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.7.6.2. Argentina: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.7.6.3. Argentina: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
- 8.7.7. Subcutaneous Immunoglobulin Market - Rest of Latin America
- 8.7.7.1. Rest of Latin America: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
- 8.7.7.2. Rest of Latin America: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
- 8.7.7.3. Rest of Latin America: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. Baxter
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Biotest
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. CSL Behring
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. GC Biopharma USA, Inc.
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Grifols
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Kamada Ltd.
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. LFB
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Nufactor
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Octapharma
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Takeda
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
